Modality
Gene Therapy
MOA
IL-23i
Target
CD38
Pathway
T-cell
Cholangiocarcinoma
Development Pipeline
Preclinical
Dec 2024
→ Jun 2026
PreclinicalCurrent
NCT08329761
2,461 pts·Cholangiocarcinoma
2024-12→2026-06·Not yet recruiting
2,461 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-233mo awayInterim· Cholangiocarcinoma
Trial Timeline
2025Q2Q3Q42026Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2026-06-23 · 3mo away
Cholangiocarcinoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08329761 | Preclinical | Cholangiocarcinoma | Not yet recr... | 2461 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |